SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049145
Filing Date
2024-04-26
Accepted
2024-04-26 16:15:06
Documents
3
Period of Report
2024-06-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A ikt-proxy-2024_def_14a.htm DEF 14A 752953
2 GRAPHIC img217168447_0.jpg GRAPHIC 80488
3 GRAPHIC img217168447_1.jpg GRAPHIC 494412
  Complete submission text file 0000950170-24-049145.txt   1541639
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39676 | Film No.: 24883939
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)